SarafSL, MolokieRE, NouraieM, SableCA, Luchtman-JonesL, EnsingGJ, et al: Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev15: 4–12, 2014PubMed
SarafSL, MolokieRE, NouraieM, SableCA, Luchtman-JonesL, EnsingGJ, et al: Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev 15: 4–12, 2014PubMed)| false
PielFB, HaySI, GuptaS, WeatherallDJ, WilliamsTN: Global burden of sickle cell anaemia in children under five, 2010-2050: Modelling based on demographics, excess mortality, and interventions. PLoS Med10: e1001484, 2013PubMed
PielFB, HaySI, GuptaS, WeatherallDJ, WilliamsTN: Global burden of sickle cell anaemia in children under five, 2010-2050: Modelling based on demographics, excess mortality, and interventions. PLoS Med 10: e1001484, 2013PubMed)| false
GBD 2021 Sickle Cell Disease Collaborators: Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: A systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol10: e585–e599, 202310.1016/S2352-3026(23)00118-7
GBD 2021 Sickle Cell Disease Collaborators: Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: A systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol 10: e585–e599, 202310.1016/S2352-3026(23)00118-7)| false
DrawzP, AyyappanS, NouraieM, SarafS, GordeukV, HostetterT, et al: Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clin J Am Soc Nephrol11: 207–215, 2016PubMed
DrawzP, AyyappanS, NouraieM, SarafS, GordeukV, HostetterT, et al: Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clin J Am Soc Nephrol 11: 207–215, 2016PubMed)| false
DerebailVK, ZhouQ, CicconeEJ, CaiJ, AtagaKI: Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality. Br J Haematol186: 900–907, 2019PubMed
DerebailVK, ZhouQ, CicconeEJ, CaiJ, AtagaKI: Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality. Br J Haematol 186: 900–907, 2019PubMed)| false
DerebailVK, CicconeEJ, ZhouQ, KilgoreRR, CaiJ, AtagaKI: Progressive decline in estimated GFR in patients with sickle cell disease: An observational cohort study. Am J Kidney Dis74: 47–55, 2019PubMed
DerebailVK, CicconeEJ, ZhouQ, KilgoreRR, CaiJ, AtagaKI: Progressive decline in estimated GFR in patients with sickle cell disease: An observational cohort study. Am J Kidney Dis 74: 47–55, 2019PubMed)| false
NaikRP, DerebailVK: The spectrum of sickle hemoglobin-related nephropathy: From sickle cell disease to sickle trait. Expert Rev Hematol10: 1087–1094, 2017PubMed
AllonM, LawsonL, EckmanJR, DelaneyV, BourkeE: Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia. Kidney Int 34: 500–506, 1988PubMed)| false
RotherRP, BellL, HillmenP, GladwinMT: The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA293: 1653–1662, 2005PubMed
RotherRP, BellL, HillmenP, GladwinMT: The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 293: 1653–1662, 2005PubMed)| false
NathKA, GrandeJP, HaggardJJ, CroattAJ, KatusicZS, SoloveyA, et al: Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol158: 893–903, 2001PubMed
NathKA, GrandeJP, HaggardJJ, CroattAJ, KatusicZS, SoloveyA, et al: Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 158: 893–903, 2001PubMed)| false
HaririE, MansourA, El AlamA, DaaboulY, KorjianS, Aoun BahousS: Sickle cell nephropathy: An update on pathophysiology, diagnosis, and treatment. Int Urol Nephrol50: 1075–1083, 2018PubMed
HaririE, MansourA, El AlamA, DaaboulY, KorjianS, Aoun BahousS: Sickle cell nephropathy: An update on pathophysiology, diagnosis, and treatment. Int Urol Nephrol 50: 1075–1083, 2018PubMed)| false
BolarinwaRA, AkinladeKS, KutiMA, OlawaleOO, AkinolaNO: Renal disease in adult Nigerians with sickle cell anemia: A report of prevalence, clinical features and risk factors. Saudi J Kidney Dis Transpl23: 171–175, 2012PubMed
BolarinwaRA, AkinladeKS, KutiMA, OlawaleOO, AkinolaNO: Renal disease in adult Nigerians with sickle cell anemia: A report of prevalence, clinical features and risk factors. Saudi J Kidney Dis Transpl 23: 171–175, 2012PubMed)| false
SarafSL, ZhangX, KaniasT, LashJP, MolokieRE, OzaB, et al: Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol164: 729–739, 2014PubMed
SarafSL, ZhangX, KaniasT, LashJP, MolokieRE, OzaB, et al: Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol 164: 729–739, 2014PubMed)| false
EnehCI, OkaforHU, IkefunaAN, UwaezuokeSN: Nocturnal enuresis: Prevalence and risk factors among school-aged children with sickle-cell anaemia in a South-east Nigerian city. Ital J Pediatr41: 66, 2015PubMed
EnehCI, OkaforHU, IkefunaAN, UwaezuokeSN: Nocturnal enuresis: Prevalence and risk factors among school-aged children with sickle-cell anaemia in a South-east Nigerian city. Ital J Pediatr 41: 66, 2015PubMed)| false
ZahrRS, DingJ, KangG, WangWC, HankinsJS, AtagaKI, et al: Enuresis and hyperfiltration in children with sickle cell disease. J Pediatr Hematol Oncol44: 358–362, 2022PubMed
ZahrRS, DingJ, KangG, WangWC, HankinsJS, AtagaKI, et al: Enuresis and hyperfiltration in children with sickle cell disease. J Pediatr Hematol Oncol 44: 358–362, 2022PubMed)| false
AlvarezO, MillerST, WangWC, LuoZ, McCarvilleMB, SchwartzGJ, et al; BABY HUG Investigators: Effect of hydroxyurea treatment on renal function parameters: Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer59: 668–674, 2012PubMed
AlvarezO, MillerST, WangWC, LuoZ, McCarvilleMB, SchwartzGJ, et al; BABY HUG Investigators: Effect of hydroxyurea treatment on renal function parameters: Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer 59: 668–674, 2012PubMed)| false
HapcaS, SiddiquiMK, KwanRSY, LimM, MatthewS, DoneyASF, et al; BEAt-DKD Consortium: The relationship between AKI and CKD in patients with type 2 diabetes: An observational cohort study. J Am Soc Nephrol32: 138–150, 2021PubMed
HapcaS, SiddiquiMK, KwanRSY, LimM, MatthewS, DoneyASF, et al; BEAt-DKD Consortium: The relationship between AKI and CKD in patients with type 2 diabetes: An observational cohort study. J Am Soc Nephrol 32: 138–150, 2021PubMed)| false
LebensburgerJD, AbanI, PernellB, KasztanM, FeigDI, HilliardLM, et al: Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy. Am J Hematol94: 417–423, 2019PubMed
VazquezB, ShahB, ZhangX, LashJP, GordeukVR, SarafSL: Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia. Am J Hematol89: 1156–1157, 2014PubMed
VazquezB, ShahB, ZhangX, LashJP, GordeukVR, SarafSL: Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia. Am J Hematol 89: 1156–1157, 2014PubMed)| false
AtagaKI, ZhouQ, SarafSL, HankinsJS, CicconeEJ, LoehrLR, et al: Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: A multicenter pooled analysis. Blood Adv6: 4461–4470, 2022PubMed
AtagaKI, ZhouQ, SarafSL, HankinsJS, CicconeEJ, LoehrLR, et al: Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: A multicenter pooled analysis. Blood Adv 6: 4461–4470, 2022PubMed)| false
DerebailVK, ZhouQ, CicconeEJ, CaiJ, AtagaKI: Longitudinal study of glomerular hyperfiltration and normalization of estimated glomerular filtration in adults with sickle cell disease. Br J Haematol195: 123–132, 2021PubMed
DerebailVK, ZhouQ, CicconeEJ, CaiJ, AtagaKI: Longitudinal study of glomerular hyperfiltration and normalization of estimated glomerular filtration in adults with sickle cell disease. Br J Haematol 195: 123–132, 2021PubMed)| false
NissO, LaneA, AsnaniMR, YeeME, RajA, CrearyS, et al: Progression of albuminuria in patients with sickle cell anemia: A multicenter, longitudinal study. Blood Adv4: 1501–1511, 2020PubMed
OlaniranKO, AllegrettiAS, ZhaoSH, AchebeMM, EneanyaND, ThadhaniRI, et al: Kidney function decline among black patients with sickle cell trait and sickle cell disease: An observational cohort study. J Am Soc Nephrol31: 393–404, 2020PubMed
OlaniranKO, AllegrettiAS, ZhaoSH, AchebeMM, EneanyaND, ThadhaniRI, et al: Kidney function decline among black patients with sickle cell trait and sickle cell disease: An observational cohort study. J Am Soc Nephrol 31: 393–404, 2020PubMed)| false
AtagaKI, ZhouQ, DerebailVK, SarafSL, HankinsJS, LoehrLR, et al: Rapid decline in estimated glomerular filtration rate in sickle cell anemia: Results of a multicenter pooled analysis. Haematologica106: 1749–1753, 2021PubMed
AtagaKI, ZhouQ, DerebailVK, SarafSL, HankinsJS, LoehrLR, et al: Rapid decline in estimated glomerular filtration rate in sickle cell anemia: Results of a multicenter pooled analysis. Haematologica 106: 1749–1753, 2021PubMed)| false
ShapiroDD, SoeungM, PerelliL, DondossolaE, SurasiDS, TripathiDN, et al: Association of high-intensity exercise with renal medullary carcinoma in individuals with sickle cell trait: Clinical observations and experimental animal studies. Cancers (Basel)13: 6022, 202110.3390/cancers13236022PubMed
ShapiroDD, SoeungM, PerelliL, DondossolaE, SurasiDS, TripathiDN, et al: Association of high-intensity exercise with renal medullary carcinoma in individuals with sickle cell trait: Clinical observations and experimental animal studies. Cancers (Basel) 13: 6022, 202110.3390/cancers13236022PubMed)| false
BritoPL, Dos SantosAF, ChweihH, FaveroME, GotardoEMF, SilvaJAF, et al: Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition. PLoS One17: e0263424, 2022PubMed
BritoPL, Dos SantosAF, ChweihH, FaveroME, GotardoEMF, SilvaJAF, et al: Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition. PLoS One 17: e0263424, 2022PubMed)| false
StabouliS, AntzaC, PapadopoulouE, TeliA, KotsisV, EconomouM: Unmasking hypertension in children and adolescents with sickle/beta-thalassemia. J Clin Hypertens (Greenwich)22: 1444–1449, 2020PubMed
GenoveseG, FriedmanDJ, RossMD, LecordierL, UzureauP, FreedmanBI, et al: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science329: 841–845, 2010PubMed
GenoveseG, FriedmanDJ, RossMD, LecordierL, UzureauP, FreedmanBI, et al: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841–845, 2010PubMed)| false
MasimangoMI, JadoulM, Binns-RoemerEA, DavidVA, SumailiEK, WinklerCA, et al: APOL1 renal risk variants and sickle cell trait associations with reduced kidney function in a large congolese population-based study. Kidney Int Rep7: 474–482, 2021PubMed
MasimangoMI, JadoulM, Binns-RoemerEA, DavidVA, SumailiEK, WinklerCA, et al: APOL1 renal risk variants and sickle cell trait associations with reduced kidney function in a large congolese population-based study. Kidney Int Rep 7: 474–482, 2021PubMed)| false
KormannR, JannotAS, NarjozC, RibeilJA, ManceauS, DelvilleM, et al: Roles of APOL1 G1 and G2 variants in sickle cell disease patients: Kidney is the main target. Br J Haematol179: 323–335, 2017PubMed
KormannR, JannotAS, NarjozC, RibeilJA, ManceauS, DelvilleM, et al: Roles of APOL1 G1 and G2 variants in sickle cell disease patients: Kidney is the main target. Br J Haematol 179: 323–335, 2017PubMed)| false
ReinerAP, RaffieldLM, FranceschiniN, AuerPL, LangeEM, NickersonDA, et al; National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine Consortium; Effect of sickle cell trait and APOL1 genotype on the association of soluble uPAR with kidney function measures in Black Americans. Clin J Am Soc Nephrol16: 287–289, 2021PubMed
ReinerAP, RaffieldLM, FranceschiniN, AuerPL, LangeEM, NickersonDA, et al; National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine Consortium; Effect of sickle cell trait and APOL1 genotype on the association of soluble uPAR with kidney function measures in Black Americans. Clin J Am Soc Nephrol 16: 287–289, 2021PubMed)| false
LiemRI, LanzkronS, D CoatesT, DeCastroL, DesaiAA, AtagaKI, et al: American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease. Blood Adv3: 3867–3897, 2019PubMed
LiemRI, LanzkronS, D CoatesT, DeCastroL, DesaiAA, AtagaKI, et al: American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease. Blood Adv 3: 3867–3897, 2019PubMed)| false
ZahrRS, RampersaudE, KangG, WeissMJ, WuG, DavisRL, et al: Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life. Haematologica104: e385–e387, 2019PubMed
ZahrRS, RampersaudE, KangG, WeissMJ, WuG, DavisRL, et al: Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life. Haematologica 104: e385–e387, 2019PubMed)| false
ArletJB, RibeilJA, ChatellierG, EladariD, De SeigneuxS, SouberbielleJC, et al: Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: A prospective observational cohort study. BMC Nephrol13: 83, 2012PubMed
ArletJB, RibeilJA, ChatellierG, EladariD, De SeigneuxS, SouberbielleJC, et al: Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: A prospective observational cohort study. BMC Nephrol 13: 83, 2012PubMed)| false
YeeMEM, LanePA, ArcherDR, JoinerCH, EckmanJR, GuaschA: Estimation of glomerular filtration rate using serum cystatin C and creatinine in adults with sickle cell anemia. Am J Hematol92: E598–E599, 2017PubMed
YeeMEM, LanePA, ArcherDR, JoinerCH, EckmanJR, GuaschA: Estimation of glomerular filtration rate using serum cystatin C and creatinine in adults with sickle cell anemia. Am J Hematol 92: E598–E599, 2017PubMed)| false
HeimlichJB, ChipokaG, ElsherifL, DavidE, EllisG, KamthunziP, et al: Nephrin as a biomarker of sickle cell glomerulopathy in Malawi. Pediatr Blood Cancer65: e26993, 201810.1002/pbc.26993PubMed
HeimlichJB, ChipokaG, ElsherifL, DavidE, EllisG, KamthunziP, et al: Nephrin as a biomarker of sickle cell glomerulopathy in Malawi. Pediatr Blood Cancer 65: e26993, 201810.1002/pbc.26993PubMed)| false
LaurentinoMR, Parente FilhoSLA, ParenteLLC, da Silva JúniorGB, DaherEF, LemesRPG: Non-invasive urinary biomarkers of renal function in sickle cell disease: An overview. Ann Hematol98: 2653–2660, 2019PubMed
LaurentinoMR, Parente FilhoSLA, ParenteLLC, da Silva JúniorGB, DaherEF, LemesRPG: Non-invasive urinary biomarkers of renal function in sickle cell disease: An overview. Ann Hematol 98: 2653–2660, 2019PubMed)| false
dos SantosTE, GonçalvesRP, BarbosaMC, da SilvaGBJr, DaherEF: Monocyte chemoatractant protein-1: A potential biomarker of renal lesion and its relation with oxidative status in sickle cell disease. Blood Cells Mol Dis54: 297–301, 2015PubMed
dos SantosTE, GonçalvesRP, BarbosaMC, da SilvaGBJr, DaherEF: Monocyte chemoatractant protein-1: A potential biomarker of renal lesion and its relation with oxidative status in sickle cell disease. Blood Cells Mol Dis 54: 297–301, 2015PubMed)| false
MillerST, WangWC, IyerR, RanaS, LaneP, WareRE, et al; BABY-HUG Investigators: Urine concentrating ability in infants with sickle cell disease: Baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatr Blood Cancer54: 265–268, 2010PubMed
MillerST, WangWC, IyerR, RanaS, LaneP, WareRE, et al; BABY-HUG Investigators: Urine concentrating ability in infants with sickle cell disease: Baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatr Blood Cancer 54: 265–268, 2010PubMed)| false
ZahrRS, HankinsJS, KangG, LiC, WangWC, LebensburgerJ, et al: Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. Am J Hematol94: E27–E29, 2019PubMed
ZahrRS, HankinsJS, KangG, LiC, WangWC, LebensburgerJ, et al: Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. Am J Hematol 94: E27–E29, 2019PubMed)| false
SasongkoTH, NagallaS: Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database Syst Rev12: CD009191, 2021PubMed
SasongkoTH, NagallaS: Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database Syst Rev 12: CD009191, 2021PubMed)| false
ThrowerA, CicconeEJ, MaitraP, DerebailVK, CaiJ, AtagaKI: Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease. Br J Haematol184: 246–252, 2019PubMed
McClellanAC, LuthiJC, LynchJR, SoucieJM, KulkarniR, GuaschA, et al: High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol159: 360–367, 2012PubMed
McClellanAC, LuthiJC, LynchJR, SoucieJM, KulkarniR, GuaschA, et al: High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol 159: 360–367, 2012PubMed)| false
Kwarteng-SiawM, HeydarpourM, BakerO, TuckerK, AchebeM: Morbidity and mortality associated with hemodialysis versus peritoneal dialysis in patients with end stage renal disease caused by sickle cell disease. Blood138[Suppl 1]: 488–489, 2021
Kwarteng-SiawM, HeydarpourM, BakerO, TuckerK, AchebeM: Morbidity and mortality associated with hemodialysis versus peritoneal dialysis in patients with end stage renal disease caused by sickle cell disease. Blood 138[Suppl 1]: 488–489, 2021)| false
LeeaphornN, ThongprayoonC, VaitlaP, HansrivijitP, JadlowiecCC, MaoSA, et al: Outcomes of kidney transplant recipients with sickle cell disease: An analysis of the 2000-2019 UNOS/OPTN database. J Clin Med10: 3063, 2021PubMed
LeeaphornN, ThongprayoonC, VaitlaP, HansrivijitP, JadlowiecCC, MaoSA, et al: Outcomes of kidney transplant recipients with sickle cell disease: An analysis of the 2000-2019 UNOS/OPTN database. J Clin Med 10: 3063, 2021PubMed)| false
BaeS, JohnsonM, MassieAB, LuoX, HaywoodCJr, LanzkronSM, et al: Mortality and access to kidney transplantation in patients with sickle cell disease-associated kidney failure. Clin J Am Soc Nephrol16: 407–414, 2021PubMed
WillisJC, AwogbadeM, HowardJ, BreenC, AbbasA, HarberM, et al: Outcomes following kidney transplantation in patients with sickle cell disease: The impact of automated exchange blood transfusion. PLoS One15: e0236998, 2020PubMed
WillisJC, AwogbadeM, HowardJ, BreenC, AbbasA, HarberM, et al: Outcomes following kidney transplantation in patients with sickle cell disease: The impact of automated exchange blood transfusion. PLoS One 15: e0236998, 2020PubMed)| false
AtagaKI, KutlarA, KanterJ, LilesD, CancadoR, FriedrischJ, et al: Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med376: 429–439, 2017PubMed
AtagaKI, KutlarA, KanterJ, LilesD, CancadoR, FriedrischJ, et al: Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 376: 429–439, 2017PubMed)| false
AtagaKI, KutlarA, CancadoR, et al: Crizanlizumab treatment is not associated with the development of proteinuria and hematuria in patients with sickle cell disease: A safety analysis from the sustain study. HemaSphere2: 305–306, 2018
AtagaKI, KutlarA, CancadoR, et al: Crizanlizumab treatment is not associated with the development of proteinuria and hematuria in patients with sickle cell disease: A safety analysis from the sustain study. HemaSphere 2: 305–306, 2018)| false
VichinskyE, HoppeCC, AtagaKI, WareRE, NdubaV, El-BeshlawyA, et al; HOPE Trial Investigators: A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med 381: 509–519, 2019PubMed)| false
NiiharaY, MillerST, KanterJ, LanzkronS, SmithWR, HsuLL, et al; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease: A phase 3 trial of L-Glutamine in sickle cell disease. N Engl J Med379: 226–235, 2018PubMed
NiiharaY, MillerST, KanterJ, LanzkronS, SmithWR, HsuLL, et al; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease: A phase 3 trial of L-Glutamine in sickle cell disease. N Engl J Med 379: 226–235, 2018PubMed)| false
FrangoulH, AltshulerD, CappelliniMD, ChenYS, DommJ, EustaceBK, et al: CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med 384: 252–260, 2021PubMed)| false
KanterJ, WaltersMC, KrishnamurtiL, MaparaMY, KwiatkowskiJL, Rifkin-ZenenbergS, et al: Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med386: 617–628, 2022PubMed
KanterJ, WaltersMC, KrishnamurtiL, MaparaMY, KwiatkowskiJL, Rifkin-ZenenbergS, et al: Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med 386: 617–628, 2022PubMed)| false